Therapy Areas: Inflammatory Diseases
Creative Medical Technology Holdings plans to treat Cachexia through AmnioStem stem cell programme under Right to Try law
9 July 2018 -

Biotechnology company Creative Medical Technology Holdings Inc (OTCQB:CELZ) reported on Friday the launch of a AmnioStem universal donor stem cell programme in treating cancer associated wasting (Cachexia) under President Trump's new Right to Try law.

The company aims at treating cancer associated wasting through the in-licensing of patent application #15/814284 entitled "Treatment of Cachexia Using Stem Cells and Products Thereof".

According to the company, the data from the AmnioStem stem cell was superior to other stem cell types at reducing inflammatory mediators, including TNF-alpha. The inflammatory mediators generated by cancer have a pivotal contribution to cancer associated weight loss, formally termed "cachexia".

Through the suppression of inflammatory mediators, as well as direct anticancer effect of amniotic fluid stem cells, the company expects the AmnioStem may provide value in the treatment of advanced cancer patients.

Cachexia is a very severe complication of cancer: weight loss during treatment is associated with more side effects of chemotherapy, fewer cycles of chemotherapy, a lower response to therapy and decreased survival. About 20% of cancer patients die due to cachexia and 50% of patients die with cachexia.

Login
Username:

Password: